(Q34013840)

English

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

John T Isaacs

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1235-1243

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Raising the bar: how HIF-1 helps determine tumor radiosensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

A history of prostate cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

The role of angiogenesis in tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

28 July 2018

Androgen receptor outwits prostate cancer drugs.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

Oral laquinimod therapy in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.514262

21 January 2018

Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

29 October 2018

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

29 October 2018

Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124623

29 October 2018

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A treatment for metastasis of murine ocular melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic effects of the quinoline-3-carboxamide linomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linomide, a novel immunomodulator that prevents death in four models of septic shock

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stimulation of wound healing by the immunomodulator LS-2616 (Linomide)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1517/13543784.2010.514262

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34013840&oldid=1856125979"